Ooki et al. [38] looked at samples from primary gastric tumors, and found genomic amplification to be present in 20 % of PRL-3-positive tumor samples, and that this amplification negatively affected the outcome of the patients. The gene discussed is PTP4A3; the disease is neoplasm.